Human cancer is largely driven by the acquisition of mutations. One class of such mutations is copy number polymorphisms, comprised of deviations from the normal diploid two copies of each autosomal chromosome per cell. We describe a probe-level allele-specific quantitation (PLASQ) procedure to determine copy number contributions from each of the parental chromosomes in cancer cells from single-nucleotide polymorphism (SNP) microarray data. Our approach is based upon a generalized linear model that takes advantage of a novel classification of probes on the array. As a result of this classification, we are able to fit the model to the data using an expectation-maximization algorithm designed for the purpose. We demonstrate a strong model fit to data from a variety of cell types. In normal diploid samples, PLASQ is able to genotype with very high accuracy. Moreover, we are able to provide a generalized genotype in cancer samples (e.g. CCCCT at an amplified SNP). Our approach is illustrated on a variety of lung cancer cell lines and tumors, and a number of events are validated by independent computational and experimental means. An R software package containing the methods is freely available.
INTRODUCTION
Over the course of the past decade, high throughput probe-based microarray technology has become a vital tool in genomic research. These microarrays contain thousands of unique nucleotide probe sequences, After specifying our model in Section 2, its fitting, via an expectation-maximization (EM) (Dempster and others, 1977) algorithm that takes advantage of the inherently discrete nature of the quantity being measured, is detailed in Section 3. In Section 4, we apply our approach to a variety of cell types, demonstrating the ability to (a) very accurately genotype over 100 000 SNPs in normal samples as either A A, AB, or B B; (b) determine copy number, genome wide, at a very high resolution in cancer samples; (c) reveal the contributions of each of the two parental chromosomes to the amplifications and deletions in these aberrant samples; and (d) infer ASCNs at each of the SNPs on the array. We provide statistical justification for the suitability of our model, and our in silico results are validated using a variety of independent in silico and in vitro methods. We conclude in Section 5 with a discussion of the relevance of our results in cancer genomics research.
ARRAY DESIGN AND MODEL SPECIFICATION
Studies employing SNP arrays have focused almost exclusively on the PM A , MM A , PM B , and MM B probe classification. However, another classification is relevant. A PM/MM pair may either be centered precisely so that the middle (13th) base of the PM probe is complementary to the SNP site or be offset (by between one and four bases in either direction). The three dichotomizations of the probe set, therefore, leave us with eight probe types: PM , where the superscript denotes centered (c) or offset (o). Our method focuses on the nucleotide-level affinities between each probe and the two target DNA sequences (corresponding to the two SNP alleles). We can count the number of bases at which each probe mismatches each of the target alleles; indeed, this information is encoded in the .CDF (Chip Definition File) provided by the manufacturer. Each probe mismatches each of the two target alleles by either 0, 1, or 2 bases, and the eight probe classes completely determine these counts. See Supplementary Figure 1 , available at Biostatistics online, for a specific example of a probe set.
Our model is motivated by the following set of principles. First, the relationship between the target quantity and probe intensity is approximately linear (with an additive term) on a log-log scale, as demonstrated in studies involving known quantities of RNA (Irizarry and others, 2003) and genomic Fig. 1 . Normal q-q plots comparing standardized residuals to the standard Gaussian distribution. a) 10 000 randomly selected residuals from the generalized linear model (2.1) fit to SNP array data from HapMap samples. b) 10 000 randomly selected residuals from the linear model (4.1) fit to SNP array data from HapMap samples.
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DNA (Huang and others, 2004) . Second, the authors in Irizarry and others (2003) justified, via spikein studies, a multiplicative stochastic error term on the standard (non-log) scale, as evidenced by larger probe variance at higher intensity levels. Third, within a probe set, each probe is complementary to a subsegment of either the forward or the reverse strand in the target DNA fragment. This "forward" or "reverse" distinction is referred to as the probe's orientation, and empirical evidence indicates differences in hybridization intensities between the orientations. Finally, it is reasonable that, aside from orientation, the main factor determining probe/target hybridization affinity within the same probe set would be the number of bases that the probe mismatches the target. More specifically, we reasonably assume that the hybridization affinity of a target for a probe is a decreasing function of the number of bases at which the probe is not complementary to the target. The exception to this assumption arises in differences in the hybridization affinities of the A and B target fragments. Since the A and B difference represents the only potential significant difference in guanine/cytosine content between the probes in a set, we have accommodated target-allele-specific differences in hybridization affinity in our model.
In an array with J probe sets/SNPs (so J > 100 000 in our case), let C
B denote the number of copies of the alleles A and B, respectively, in the ith sample at the jth SNP site ( j = 1, . . . , J ). The model we propose for the normalized, log-transformed intensity Y (i jk) of probe k in the probe set for SNP j in an array interrogating sample i is
Here O jk = F (forward) or R (reverse) denotes the orientation of the probe, A jk , B jk = 0, 1, or 2 indicate the number of bases at which the probe mismatches the A and B allele targets, respectively, and γ
represent the unwanted background contributions of optical noise and nonspecific binding to the forward and reverse orientation probe intensities, respectively. One may think of these last terms as representing the signal from a probe whose target is completely absent. The independent, normally distributed, mean zero error terms e (i jk) are meant to capture additional sources of variation. They are assumed to have standard deviation σ ( j)
R when O jk = R. The distributions of these error terms are the same for any fixed values of j and O jk , but are allowed to vary for different probe sets and different orientations within the same probe sets. Finally, we have found in practice that hybridization intensities between probes and targets that mismatch at two bases are indistinguishable from background noise, and thus we fix α
Thus, the parameters of interest for each probe set/SNP j are γ
1F , and β 3. MODEL FITTING AND COPY NUMBER INFERENCE Equation (2.1) models mean log-transformed probe intensity as a log-linear function of copy number. There are some complications to fitting the model. First, the log transformation on the right side of the equation precludes the use of ordinary least squares. However, the model is a generalized linear model (McCullagh and Nedler, 1989) with an exponential link, and thus we fit the model using iteratively reweighted least squares (IRLS). A more severe obstacle to model fitting is the fact that we usually know neither parameter nor covariate values C
B a priori. We do know that, in a normal sample, each SNP is in one of three states-A A, AB, or B B. This implies three different covariate combinations, and therefore, an EM algorithm is a natural approach to fitting the model to diploid data. The first step is to quantile normalize (Bolstad and others, 2003) results are comparable across arrays by removing differences (such as overall brightness) unrelated to the underlying molecular biology. After estimating the model parameters from the normal references using the EM procedure, we fit to data from cancer samples (again using IRLS), which yields raw ASCNs at each SNP site. Further processing produces our final ASCN and PSCN calls. In this section, we describe each of these steps.
Model calibration on normal samples
For SNP arrays, normal samples provide a convenient basis for model fitting and testing, as the pairwise ASCN sums C
B are known to be two. We exploit this fact to find estimatesγ
1F , and β ( j) 1R , respectively. Model (2.1) may be fit to (normalized) probe intensities using an EM algorithm, and the genotyping inferences automatically result. Details of this procedure are given in the Appendix.
PSCNs and ASCNs in tumor samples
Supplementary Figure 2 , available at Biostatistics online, gives a diagrammatic overview of the procedure to obtain ASCNs and PSCNs from (normalized) probe-level data from tumor sample i 0 . We assume that parameters have been estimated as above from a battery of normal samples, and we replace the parameters in the model with these estimates at each SNP. Our model becomes
We may now obtain raw ASCN inferences (C
B raw ) via IRLS as applied to Model (3.1). In effect, we are treating the covariates C
as parameters to be estimated. The ASCN inferences at this stage are "raw" because we have not yet taken advantage of the fact that total copy number is locally constant; that is, chromosomal copy number aberrations occur in discrete segments, typically spanning many consecutive SNP sites. We may therefore apply a smoothing or break point procedure to the pairwise sums of the raw ASCNs, mapped to their genomic locations. For our study, we have employed the GLAD algorithm (Hupé and others, 2004) because of its sensitivity, specificity, and computational efficiency. GLAD attempts to detect chromosomal segments with constant total copy number using an adapted weights smoothing (Polzehl and Spokoiny, 2000) break point-detection algorithm. Our inferred total copy number T (i 0 s) for a GLAD-determined segment s is the rounded median of the pairwise raw ASCN sums in the segment.
Next, we infer PSCNs in each segment s from inferred total copy number T (i 0 s) and raw ASCNs as follows. First, if the inferred total copy number is 0 or 1, then our PSCN calls are obviously (major chromosome, minor chromosome) = (0, 0) or (1, 0), respectively. If not, we next decide whether LOH has occurred. When a matched normal sample is available, this is easily determined by querying for homozygosity SNPs that are heterozygous in the matched normal. In the absence of a matched normal sample, we make use of the fact that the average heterozygosity rate for SNPs on the array is approximately 30% (Affymetrix, 2004) . Therefore, we may think of the number of homozygous SNPs in a segment with m SNPs as an approximate Binomial(m, 0.7) variable. Making a Bonferroni correction for the number S of segments, we call LOH for segments in which the number of homozygous SNPs is greater than the 1−0.05/S quantile in the Binomial(m, 0.7) distribution (here a SNP j is assumed to be homozygous when the rounded minimum(C regard to PSCN, and our PSCN call is (T (i 0 s) − ν, ν), where
rounded to the nearest integer. Both sums in this expression are taken over all heterozygous SNPs j in segment s. Finally, we determine ASCNs from PSCNs and raw ASCNs at each SNP j. If the SNP is heterozygous, then the ASCNs are the same as the PSCNs, with the copy number of the major SNP allele (as determined by raw ASCNs) identical to that of the major parental chromosome segment. If the SNP is homozygous, the allele with the higher raw ASCN is assigned ASCN T (i 0 s) , and the other 0.
APPLICATION TO NORMAL AND CANCER DATA

Data sets
The SNP array data are encoded in a pair of .cel files (one for each chip type) for each sample. We employed data from 21 normal samples in our study. These data include 24 .cel files from Zhao and others (2005) that corresponded to all the normal samples in that study, as well as 18 .cel files (corresponding to samples NA6985, NA6991, NA6993, NA12707, NA12716, NA12717, NA12801, NA12812, and NA12813) that were generated as part of the International HapMap Project (http://www.hapmap.org). The latter samples, which we refer to as the HapMap data set, are available for download at the Affymetrix web site (http://www.affymetrix.com). For cancer samples, we used .cel files from 12 lung tumors and cell lines (see Tables 2 and 3 ) that were generated in Zhao and others (2005) .
Application to normal samples
To validate the assumptions of our model, we first fit it to the HapMap data set. We examined the residuals from the model to check the assumption of normally distributed error terms. Note that, although the error terms are assumed to be identically distributed within same-orientation subsets of a probe set, their variances are allowed to differ across probe sets and orientations. We, therefore, constructed a normal quantile-quantile (q-q) plot (Figure 1a ) of the standardized residuals, with the understanding that the model implies a standard normal distribution for these across all probe sets. For clarity, we randomly selected 10 000 such residuals to plot. To demonstrate the necessity of the log-log transformation, we also plotted the standardized residuals resulting from fitting the linear model for each j = 1, . . . , J and k = 1, . . . , 40. We fit (4.1) using the EM algorithm as with Model (2.1), except that the M-step involves ordinary least squares rather than IRLS. The resulting q-q plot (Figure 1b) clearly shows a severe departure from normality. This demonstrates the improvement of our new generalized linear model-based approach over the previous work.
As mentioned above, probes on SNP arrays have traditionally been classified in PM/MM or A allele/B allele terms. The advantage of our approach-classifying probes by base MM count-can be seen in Figure 2 . The first scatterplot shows the mean MM o A intensity versus the mean MM c A intensity across 10 782 HapMap sample SNPs. Each point represents one orientation (F or R) of one SNP for one sample. The means are taken over all MM c A (x-axis) or MM o A (y-axis) probe intensities for the given orientation/SNP/sample. Each point is colored according to HapMap genotype. Although the traditional classification treats these two probe types as being equivalent measures, there is clearly a separation of the three genotypes visible in the plot. As expected, the centered probes generally have a greater affinity for the B target than the offset probes, and both types have roughly the same affinity for the A target. This effect is even more dramatic when the background γ term is subtracted, as shown in Figure 2b . These figures show that the practice of ignoring MM probes, as some approaches do, in fact discards relevant information. Moreover, if we construct a similar plot for MM c A versus MM c B (Figure 2c ), no separation of the genotypes is discernible, even though the traditional classification would treat these two intensities as being measures of separate quantities.
Many of the SNPs in the HapMap data set have been independently genotyped, using a variety of genotyping platforms. Of these, 1198 were genotyped by at least two different HapMap centers. Calls that were concurrent among at least two different centers may be considered as being very close to ground truth, and we employed these as the "gold standard" data set against which we compared our PLASQ method. As shown in Table 1 , our method performs quite well. The rate of agreement between PLASQ and the HapMap concordant calls is similar to the HapMap Project's concordance rate, and our No Call rate is considerably lower. We should note that 16 sample SNPs in the Table for which PLASQ called A A and the HapMap effort called B B are all from the same two SNP loci. Close inspection of the raw array data from these SNPs reveals a strong A A signal (data not shown). Thus, we suspect that this is simply a case of an error being made by Affymetrix when the " A" and "B" labels were assigned to the nucleotide residues. In any case, the results in the table clearly indicate that the model captures the relevant aspects of the data, and underscore the validity of our EM fitting approach.
Application to lung cancer
We applied our PLASQ method to SNP array data from 12 lung cancer samples, using the 12 diploid samples from the same study as normal references on which to train the model. Figure 3 shows an example of a genome-wide view of PSCN for one of these samples, the cell line H2087. Note that LOH is clearly identifiable as a region comprised of only the major chromosome (all green). For example, all of one copy of chromosome 13 appears to be lost, though the total copy number remains at two. This phenomenon is referred to as copy-neutral LOH.
To assess the accuracy of our method, we compared our results to polymerase chain reaction (PCR) -based copy number estimates. A total of 16 deletions and 10 amplifications in our 12 lung cancer samples were previously PCR-measured in Zhao et al. (2005) . These PCR measurements quantified only total (not allele-specific) copy number, so we have developed an experimental method to measure copy number on an allele-specific basis. This quantitative PCR-based method is described in LaFramboise et al. (2005) . Tables 2 and 3 compare the PLASQ results with the PCR results. As quantitative real-time PCR is a very sensitive technique, the putative homozygous deletions in Table 2 are most likely valid. Our PLASQ procedure is able to identify each deletion, and in fact they are almost always apparent at the raw ASCN level. The estimates for amplifications are, however, not as concordant. Although PLASQ detects each amplification, the results tend to be lower than the PCR-based estimates in the higher-copy-number alleles. This is quite possible due to well-known saturation effects in oligonucleotide arrays (Naef and others, 2003) , and is difficult to mitigate. On the other hand, it is possible that our allele-specific quantitative PCR technique may not be a precise measure. In any case, an argument could be made that these errors are of little consequence, as the aim in these studies is to identify amplifications, deletions, and the haplotypes involved, all of which PLASQ can clearly uncover.
DISCUSSION
Human cancer is driven by the acquisition of genomic changes in the cell. One extremely important class of such changes is amplifications and deletions-deviations from the normal two copies of each chromosome in a cell. Regions of amplification may harbor cancer-causing oncogenes, while deletions often contain tumor suppressor genes. The localization of such alterations is, therefore, a central goal in cancer research. We have presented a procedure, PLASQ, for determining the copy numbers of SNP alleles and parental chromosomes in cancer cells from SNP array data. Our SNP allele copy number result is particularly of interest in LOH determination, since existing methods often mistakenly call LOH, where in fact allelic balance (due to amplification of one allele) has occurred, resulting in apparent (though false) homozygosity. We avoid these false LOH calls by taking into account the contribution to copy number from both alleles. Two recent papers (Ishikawa and others, 2005; Nannya and others, 2005) have been published that aim to determine PSCN. However, their approaches require additional SNP array data from matched normal cells, which are often unavailable. Moreover, both methods ignore MM probes, and thereby discard half of the information available in SNP arrays. As we have shown, MM probes are in fact informative.
Finally, we should mention two potential weaknesses of our approach. First, we are assuming a diploid copy number two in autosomal chromosomes of normal cells. Recent studies (Iafrate and others, 2004; Sebat and others, 2004) have uncovered copy number polymorphisms in normal cells. Given that our approach (and all others that we are aware of) compares signal intensities to normal references, this could in theory present a problem. In practice, however, we feel that this problem is mitigated by the fact that we use a sizable collection of normal reference samples, and that polymorphic genomic regions common to most normal reference samples are likely rare, small in length, or both. A second concern is our practice of fitting the model to normal samples and then applying the result to data from tumors. We are implicitly assuming that the model parameters are appropriate outside of the range of covariates with Downloaded from https://academic.oup.com/biostatistics/article-abstract/8/2/323/231312 by guest on 12 March 2019 which they were estimated. Although this is indeed a concern (and may be partially to blame for copy number underestimation of high-level amplifications), we would argue that the results shown in Tables 2  and 3 demonstrate the value of the model, even for aberrant copy numbers.
All procedures described herein are available in an R (R Development Core Team, 2006) package, freely downloadable at http://genome.dfci.harvard.edu/∼tlaframb/PLASQ.
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APPENDIX A
We describe in detail the EM approach to fitting Model (2.1) to probe-level SNP array data from normal samples.
A.1 Notation
Fix an arbitrarily chosen SNP j 0 . Suppose that we have N normal samples. For i = 1, . . . , N and l = 0, 1, 2, let Z i j 0 l denote the (unobserved) indicator variable I (C (i j 0 ) A = l). Model (2.1) may be rewritten, using this notation, as
